Company intelligence
MGI
Leading Life Science Innovation
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and has established research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGl empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGl also stands out as one of the only providers of a full-stack product portfolio that spans three core segments: SEQ ALL (short-and long-read sequencing),GLI (Generative Lab Intelligence), and Multi-Omics.
Verified activity
Signals from MGI
7 published signals
Presence & Recognition
MGI is attending the European Congress of Pathology 2026 at Booth 332 in Stockholmsmässan on 12-16 September 2026.
Reported by MGI
Presence & Recognition
MGI is hosting a 2026 STOmics Spatial Bioinformatics Webinar Series from September to December.
Reported by MGI
Presence & Recognition
MGI attended the XXXVII Congresso Brasileiro de Genética Médica e Genômica in São Luís, Maranhão.
Reported by MGI
Presence & Recognition
MGI is attending the BIOHK 2026 conference in Hong Kong next week.
Reported by MGI
Research & Knowledge
MGI technology powered by the research team led by Prof. Yannis Pitsiladis at the Centre for Exercise Science and Medicine of Hong Kong Baptist University is pioneering a groundbreaking solution using transcriptomics to detect molecular signatures left behind after prohibited substances are no longer directly detectable.
Reported by MGI
Legal & Regulatory
MGI partner Vision Medicals has received NMPA approval for its Respiratory Pathogen Nucleic Acid Detection Kit (cPAS) for clinical application.
Reported by MGI
Research & Knowledge
MGI published an August newsletter exploring how its DCSP framework integrates DNA, Cell, Spatial, and Proteomics to empower the global life science community.
Reported by MGI